RxDoctor Payments Data

Baxter Montgomery, MD

Cardiovascular Disease · Houston, TXNPI 1295728293

Payments from drug & device makers

$8,401in general payments, 2019–2025

Across 71 payments — averaging $118.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$7K
  • Johnson & Johnson$301
  • Novo Nordisk$156
  • Janssen Scientific Affairs, LLC$132
  • Novartis$118
  • Tactile Systems Technology Inc$100
  • plus $737 from 18 others

What the payments were for

  • Consulting fees$6,41076%
  • Travel & lodging$3174%
  • Food & beverage$1,67520%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,401 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$1,355,032
Medicare patients
322
Services billed
16,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$66,423
EntrestoSacubitril/Valsartan21$28,878
XareltoRivaroxaban24$21,921
EdarbiAzilsartan Medoxomil19$9,684
JardianceEmpagliflozin13$8,634
Nifedipine ErNifedipine115$3,536
Nebivolol Hcl27$1,760
Carvedilol120$888
Bumetanide19$622
Amiodarone Hcl32$544
Amlodipine Besylate99$458
Potassium Chloride19$374
Rosuvastatin Calcium21$334
Olmesartan Medoxomil16$331
Metoprolol Succinate24$267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$118$28,87821 claims
Johnson & JohnsonXarelto$301$21,92124 claims
Arbor Pharmaceuticals, Inc.Edarbi$12$9,68419 claims
Boehringer IngelheimJardiance$70$8,63413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →